by The global nephrology drugs market size accounted for US$ 15.9 Bn in 2022 and is projected to reach around USD 27.2 Bn by 2032, growing at a CAGR of 5.52% from 2023 to 2032.
Report Summary
The global nephrology drugs market report provides a Point-by-Point and In-Depth analysis of global market size, regional and country-level market size, market share, segmentation market growth, competitive landscape, sales analysis, opportunities analysis, strategic market growth analysis, the impact of domestic and global market key players, value chain optimization, trade regulations, recent developments, product launches, area marketplace expanding, and technological innovations.
The study offers a comprehensive analysis on diverse features, including production capacities, demand, product developments, revenue generation, and sales in the nephrology drugs market across the globe.
A comprehensive estimate on the nephrology drugs market has been provided through an optimistic scenario as well as a conservative scenario, taking into account the sales of nephrology drugs during the forecast period. Price point comparison by region with global average price is also considered in the study.
Download Access to a Free Copy of Our Latest Sample Report@ https://www.precedenceresearch.com/sample/2577
Nephrology Drugs Market Report Scope
| Report Coverage | Details |
| Market Size in 2023 | USD 15.9 Billion |
| Market Size by 2032 | USD 27.2 Billion |
| Growth Rate from 2023 to 2032 | CAGR of 5.52% |
| Largest Market | North America |
| Second Largest Market | Europe |
| Fastest Growing Market | Asia Pacific |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | By Drug Class, By Route of Administration and By Distribution Channel |
Key Highlights:
Reports Coverage: It incorporates key market sections, key makers secured, the extent of items offered in the years considered, worldwide containerized nephrology drugs market and study goals. Moreover, it contacts the division study gave in the report based on the sort of item and applications.
Market Outline: This area stresses the key investigations, market development rate, serious scene, market drivers, patterns, and issues notwithstanding the naturally visible pointers.
Market Production by Region: The report conveys information identified with import and fare, income, creation, and key players of every single local market contemplated are canvassed right now.
Also Read: Palm Oil Market Size To Cross USD 106.3 Bn By 2032
Nephrology Drugs Market Players
The report includes the profiles of key nephrology drugs market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information, key development in past five years.
Major companies operating in this area
- AstraZeneca
- AbbVie Inc.
- Akebia Therapeutics, Inc.
- Amgen Inc.
- F. Hoffmann-La Roche
- FibroGen Inc.
- Johnson & Johnson Inc.
- Pfizer Inc.
- Teva Pharmaceutical Industries Limited
- Reata Pharmaceuticals, Inc.
- GlaxoSmithKline plc.
- Ardelyx, Inc.
- Boehringer Ingelheim International GmbH
- Novo Nordisk A/S
- Novartis AG
Market Segmentation
By Drug Class
- ACE Inhibitors
- Angiotensin Receptor Blockers (ARBs)
- B-Blockers
- Calcium Channel Blockers
- Loop Diuretics
- Erythropoiesis-Stimulating Agents (ESAs)
- Phosphate Binders
- Others
By Route of Administration
- Oral
- Subcutaneous
- Intravenous
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Regional Segmentation
- North America (U.S., Canada, Mexico)
- Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
- Asia-Pacific (China, Japan, India, Southeast Asia and Rest of APAC)
- Latin America (Brazil and Rest of Latin America)
- Middle East and Africa (GCC, North Africa, South Africa, Rest of MEA)
Research Methodology
Secondary Research
It involves company databases such as Hoover’s: This assists us to recognize financial information, the structure of the market participants and industry’s competitive landscape.
The secondary research sources referred in the process are as follows:
- Governmental bodies, and organizations creating economic policies
- National and international social welfare institutions
- Company websites, financial reports and SEC filings, broker and investor reports
- Related patent and regulatory databases
- Statistical databases and market reports
- Corporate Presentations, news, press release, and specification sheet of Manufacturers
Primary Research
Primary research includes face-to-face interviews, online surveys, and telephonic interviews.
- Means of primary research: Email interactions, telephonic discussions and Questionnaire-based research etc.
- In order to validate our research findings and analysis, we conduct primary interviews of key industry participants. Insights from primary respondents help in validating the secondary research findings. It also develops Research Team’s expertise and market understanding.
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Nephrology Drugs Market
5.1. COVID-19 Landscape: Nephrology Drugs Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Nephrology Drugs Market, By Drug Class
8.1. Nephrology Drugs Market, by Drug Class, 2023-2032
8.1.1 ACE Inhibitors
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Angiotensin Receptor Blockers (ARBs)
8.1.2.1. Market Revenue and Forecast (2020-2032)
8.1.3. B-Blockers
8.1.3.1. Market Revenue and Forecast (2020-2032)
8.1.4. Calcium Channel Blockers
8.1.4.1. Market Revenue and Forecast (2020-2032)
8.1.5. Loop Diuretics
8.1.5.1. Market Revenue and Forecast (2020-2032)
8.1.6. Erythropoiesis-Stimulating Agents (ESAs)
8.1.6.1. Market Revenue and Forecast (2020-2032)
8.1.7. Phosphate Binders
8.1.7.1. Market Revenue and Forecast (2020-2032)
8.1.8. Others
8.1.8.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Nephrology Drugs Market, By Route of Administration
9.1. Nephrology Drugs Market, by Route of Administration, 2023-2032
9.1.1. Oral
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Subcutaneous
9.1.2.1. Market Revenue and Forecast (2020-2032)
9.1.3. Intravenous
9.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Nephrology Drugs Market, By Distribution Channel
10.1. Nephrology Drugs Market, by Distribution Channel, 2023-2032
10.1.1. Hospital Pharmacies
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Retail Pharmacies
10.1.2.1. Market Revenue and Forecast (2020-2032)
10.1.3. Online Pharmacies
10.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 11. Global Nephrology Drugs Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.1.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.1.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.1.4.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.1.4.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.1.5.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.1.5.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.2.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.2.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.2.4.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.2.4.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.2.5.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.2.5.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.2.6.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.2.6.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.2.7.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.2.7.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.3.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.3.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.3.4.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.3.4.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.3.5.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.3.5.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.3.6.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.3.6.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.3.7.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.3.7.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.4.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.4.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.4.4.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.4.4.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.4.5.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.4.5.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.4.6.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.4.6.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.4.7.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.4.7.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.5.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.5.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.5.4.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.5.4.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.5.5.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.5.5.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
Chapter 12. Company Profiles
12.1. AstraZeneca
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. AbbVie Inc.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Akebia Therapeutics, Inc.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Amgen Inc.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. F. Hoffmann-La Roche
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. FibroGen Inc.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Johnson & Johnson Inc.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Pfizer Inc.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Teva Pharmaceutical Industries Limited
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Reata Pharmaceuticals, Inc.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
